TCT 2015 Roundup: St. Jude Medical’s new HeartMate PHP pump
St. Jude Medical (NYSE:STJ) said today that its newly acquired HeartMate PHP heart pump met its safety and efficacy endpoints in the Shield I trial used to back its CE Mark approval last summer.
The results from Shield I’s 1st 30 patients led to the CE Mark nod in July. Today St. Jude said data from 46 subjects passed the primary safety endpoint of a composite of major adverse events and the primary efficacy endpoint of freedom from hemodynamic compromise during percutaneous coronary intervention.
The study results, released today at the annual Transcatheter Cardiovascular Therapeutics conference in San Francisco...
Source: Mass Device - October 14, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Catheters Clinical Trials Elixir Medical Corp. Micell Technologies Inc. St. Jude Medical Stentys TCT 2015 Tryton Medical Inc. Source Type: news
Salutaris Medical Devices Announces 510(k) Clearance
Salutaris Medical Devices (SalutarisMD) announced that its SMD Sr90-1 Radionuclide Brachytherapy Source (RBS) received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The SMD Sr90-1 RBS is indicated for episcleral brachytherapy of tumors and benign growths, and is intended for use within a manual brachytherapy applicator system. (Source: Medical Design Online News)
Source: Medical Design Online News - September 8, 2015 Category: Medical Equipment Source Type: news
Theragenics to Distribute the AccuBoost(R) Technology for Treatment of Early Stage Breast Cancer
Non-Invasive Brachytherapy Treatment Supplements Breast Conservation Therapy
BUFORD, Ga.--(Healthcare Sales & Marketing Network)--Theragenics Corporation®, a medical device company serving the cancer treatment and surgical product markets, has reach... Devices, Oncology, DistributionTheragenics, Advanced Radiation Therapy, AccuBoost, brachytherapy, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 30, 2015 Category: Pharmaceuticals Source Type: news
Theragenics to distribute ART's AccuBoost
Brachytherapy seed manufacturer Theragenics and women's health firm Advanced (more) (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 30, 2015 Category: Radiology Source Type: news
Cianna Medical Raises $8 Million Through Recent Financing Transactions
$4 Million Through GE Capital and $4 Million Through Internal Equity Round
ALISO VIEJO, CA--(Healthcare Sales & Marketing Network) - Cianna Medical, Inc., a medical device company dedicated to improving the quality of life for women affected by breast c... Devices, Oncology, Venture CapitalCianna Medical, SAVI SCOUT, SAVI applicator, brachytherapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 16, 2015 Category: Pharmaceuticals Source Type: news
GE Capital backs Cianna Medical in $8m round
Cianna Medical said today that it raised $8 million for its Savi Scout breast cancer device, including a $4 million debt round from GE Capital and another $4 million equity round from existing backers.
Aliso Viejo, Calif.-based Cianna’s Savi Scout is designed to produce audible and visual indicators surgeons can use to tag cancerous tissue during lumpectomy and biopsy procedures.
The surgeon uses a hand piece that emits infrared light and electromagnetic waves to locate a reflector placed in target tissue as long as a week before surgery. After reaching the surgical bulls-eye, the surgeon takes out the target tissu...
Source: Mass Device - July 16, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Surgical Women's Health Breast Cancer Cianna Medical Source Type: news
Varian shows software upgrade at AAPM 2015
Varian Medical Systems has introduced a faster version of its VariSeed brachytherapy (more) (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 15, 2015 Category: Radiology Source Type: news
Breast cancer treatment with fewer potential side effects has equally good patient outcomes, UCLA study shows
A new study by UCLA scientists has found that women diagnosed with breast cancer and treated with a one-week regimen of partial breast radiation after the surgical removal of the tumor, or lumpectomy, saw no increase in cancer recurrence or difference in cosmetic outcomes compared to women who received radiation of the entire breast for a period of up to six weeks after surgery. The study is one of the largest ever done on partial breast irradiation.
The study lasted two decades and was led by Dr. Mitchell Kamrava, an assistant professor of radiation oncology at UCLA and member of the Jonsson Comprehensive Cancer Center. ...
Source: UCLA Newsroom: Health Sciences - June 26, 2015 Category: Universities & Medical Training Source Type: news
IsoRay faces lawsuits alleging fudged clinical data
IsoRay (NYSE:ISR) is facing putative class-action lawsuits from shareholders accusing the company of making false or misleading statements about a clinical trial of its Cesium 131 brachytherapy seeds designed to treat cancer.
The lawsuits, from at least 3 different shareholders, claim that IsoRay made false statements about a clinical study of Cesium 131. The study was the 1st major peer-reviewed study of the brachytherapy seeds.
The Richland, Wash.-based company’s press release came out May 20, 1 day after the study was published in the journal Brachytherapy. IsoRay’s release claimed a 100% survival rate ...
Source: Mass Device - June 15, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Clinical Trials Legal News Wall Street Beat IsoRay Source Type: news
My hysterectomy for cancer – Carol’s story
The post My hysterectomy for cancer – Carol’s story appeared first on Hysterectomy Association.
In March 2013 I went for my routine annual smear, I have been on yearly smears since the birth of my last daughter in 1997. Two weeks later I received a letter with an appointment to attend the colposcopy clinic which was scheduled for two weeks later (end of April).
I attended this and was told I had cin3 pre-cancer cells on my cervix. They tried to do the leep whilst I was there but were unable to do it as the pain was horrendous. So I was advised it needed to be done under a general. The end of May I had my leep ...
Source: The Hysterectomy Association - June 9, 2015 Category: OBGYN Authors: Linda Tags: Your Stories cancer cervical cancer Source Type: news
My hysterectomy for cancer – Carol ’ s story
In March 2013 I went for my routine annual smear, I have been on yearly smears since the birth of my last daughter in 1997. Two weeks later I received a letter with an appointment to attend the colposcopy clinic which was scheduled for two weeks later (end of April).
I attended this and was told I had cin3 pre-cancer cells on my cervix. They tried to do the leep whilst I was there but were unable to do it as the pain was horrendous. So I was advised it needed to be done under a general. The end of May I had my leep done. I took a week off work to rest, then went back to work to await the results. On June 27th I went to my...
Source: The Hysterectomy Association - June 9, 2015 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health cancer cervical cancer hysterectomy stories Source Type: news
My hysterectomy for cancer – Carol ’ s story
In March 2013 I went for my routine annual smear, I have been on yearly smears since the birth of my last daughter in 1997. Two weeks later I received a letter with an appointment to attend the colposcopy clinic which was scheduled for two weeks later (end of April).
I attended this and was told I had cin3 pre-cancer cells on my cervix. They tried to do the leep whilst I was there but were unable to do it as the pain was horrendous. So I was advised it needed to be done under a general. The end of May I had my leep done. I took a week off work to rest, then went back to work to await the results. On June 27th I went to my...
Source: The Hysterectomy Association - June 9, 2015 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health cancer cervical cancer hysterectomy stories Source Type: news
Backing Off From Brachytherapy? Deciphering the DeclineBacking Off From Brachytherapy? Deciphering the Decline
The declining use of brachytherapy is an enigma among radiation oncologists. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 5, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Brachytherapy Benefits in High-Risk Prostate CancerBrachytherapy Benefits in High-Risk Prostate Cancer
Brachytherapy after external beam radiotherapy (EBRT) doubles the chance of progression-free survival at 9 years when compared with EBRT alone. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 28, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
